Haematologische Onkologische Praxis im Medicum

The Haematologische Onkologische Praxis im Medicum focuses on neoplasms, primarily studying HR+/HER2- negative breast cancer in both early and metastatic stages.

• Long‑term disease stabilization after stopping CDK4/6 inhibitors combined with continued endocrine therapy.
• Comparison of ribociclib plus endocrine therapy versus standard chemotherapy to improve invasive disease‑free survival.

This work supports the development of more durable treatment strategies for patients in Bremen and beyond.

Clinical investigations target HR+/HER2- negative early breast cancer and its metastatic counterpart, aiming to refine therapeutic choices.

• Assessment of disease control when CDK4/6 inhibitors are discontinued after at least 12 months of stable response.
• Evaluation of a dynamic marker‑guided approach using ribociclib in intermediate‑risk early disease.

Results aim to personalize care and extend survival for patients with hormone‑responsive disease.

The site evaluates novel combinations of endocrine therapy with targeted agents to boost outcomes in hormone‑responsive cancers.

• Investigating the superiority of ribociclib plus endocrine therapy on 5‑year distant disease‑free survival.
• Monitoring quality of life during low‑intervention trials of CDK4/6 inhibitor discontinuation.

By integrating biomarkers and patient‑reported outcomes, the practice seeks to set new standards for quality of life and long‑term survival.